MET and lung cancer: Finally, the current bsAbs are mainly targeted at some mature targets (e.g., EGFR, PD1, etc.), and breakthroughs are urgently needed in the mining of new lung cancer-specific targets (e.g., c-MET, HER3) and TME regulation strategies (e.g., combining with anti-angiogenic drugs).